| Duane Russell Hospenthal, MD, PHD | |
|
8715 Village Dr Ste 514, San Antonio, TX 78217-5407 | |
| (210) 370-9922 | |
| (210) 545-5616 |
| Full Name | Duane Russell Hospenthal |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 33 Years |
| Location | 8715 Village Dr Ste 514, San Antonio, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013907831 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 4301062322 (Michigan) | Secondary |
| 207RI0200X | Internal Medicine - Infectious Disease | P2264 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Hospital | San antonio, TX | Hospital |
| Baptist Medical Center | San antonio, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| San Antonio Infectious Diseases Consultants | 6800871286 | 19 |
News Archive
Researchers have identified a set of criteria that, when combined with a measure of kidney function, could help identify patients who are likely to receive a survival benefit from a combined heart and kidney transplant, according to a report in the March issue of Archives of Surgery.
For children and adolescents with HIV infection, the recent Food and Drug Administration (FDA) approval of the use of raltegravir, an antiretroviral drug that slows the spread of HIV infection, offers a new weapon to treat HIV infection in children.
A novel laboratory-synthesized molecule based in natural compounds found in marine gliding bacteria - known as marinoquinolines - is a strong candidate for the development of a new antimalarial drug.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.
› Verified 7 days ago
| Entity Name | San Antonio Infectious Diseases Consultants |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386634319 PECOS PAC ID: 6800871286 Enrollment ID: O20040621000741 |
News Archive
Researchers have identified a set of criteria that, when combined with a measure of kidney function, could help identify patients who are likely to receive a survival benefit from a combined heart and kidney transplant, according to a report in the March issue of Archives of Surgery.
For children and adolescents with HIV infection, the recent Food and Drug Administration (FDA) approval of the use of raltegravir, an antiretroviral drug that slows the spread of HIV infection, offers a new weapon to treat HIV infection in children.
A novel laboratory-synthesized molecule based in natural compounds found in marine gliding bacteria - known as marinoquinolines - is a strong candidate for the development of a new antimalarial drug.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Duane Russell Hospenthal, MD, PHD 8042 Wurzbach Rd Ste 280, San Antonio, TX 78229-3863 Ph: (210) 614-8100 | Duane Russell Hospenthal, MD, PHD 8715 Village Dr Ste 514, San Antonio, TX 78217-5407 Ph: (210) 370-9922 |
News Archive
Researchers have identified a set of criteria that, when combined with a measure of kidney function, could help identify patients who are likely to receive a survival benefit from a combined heart and kidney transplant, according to a report in the March issue of Archives of Surgery.
For children and adolescents with HIV infection, the recent Food and Drug Administration (FDA) approval of the use of raltegravir, an antiretroviral drug that slows the spread of HIV infection, offers a new weapon to treat HIV infection in children.
A novel laboratory-synthesized molecule based in natural compounds found in marine gliding bacteria - known as marinoquinolines - is a strong candidate for the development of a new antimalarial drug.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.
› Verified 7 days ago
Dr. Dennis Anthony Ruff, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 8307 Gault Ln, San Antonio, TX 78209 Phone: 210-798-5112 | |
Zarema J Singson, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5223 Hamilton Wolfe Rd, San Antonio, TX 78229 Phone: 210-614-1234 Fax: 210-614-0952 | |
Sapna Raghunathan, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 8300 Floyd Curl Dr, San Antonio, TX 78229 Phone: 210-450-9490 Fax: 210-450-6065 | |
Dr. Jonathan Edward Slovik, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4502 Medical Dr, San Antonio, TX 78229 Phone: 210-358-4000 Fax: 210-358-0647 | |
Mr. Paul Joseph Fanucchi, NP Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: Marianist Residence, 520 Fondham, San Antonio, TX 78228 Phone: 210-434-4157 Fax: 210-433-6005 | |
Socrates B Aramburu, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1100 Mccullough Ave, Suite 300, San Antonio, TX 78212 Phone: 210-271-3204 Fax: 210-222-2761 | |
David H White, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 6800 Ih 10 W, Ste 350, San Antonio, TX 78201 Phone: 210-616-0801 |